EU Big Data Report Takeaways Ready ‘In Weeks’
Executive Summary
EU regulators have been working on a project to help determine the potential role of big data in medicines assessment for almost two years. They will soon be ready to release their keenly awaited conclusions.
You may also be interested in...
EU ‘Big Data’ Report: Big Opportunities – And Big Challenges
EU regulators have produced the first fruits of their ambitious “big data” project aimed at ensuring that the EU drug regulatory system can make full use of the rapidly increasing volume and complexity of data being gathered across multiple settings in the healthcare area.
Big Data In Medicines Regulation Will Need ‘Considerable Change In Mindset’
Changing mindsets, technologies outpacing regulatory frameworks, intense international collaboration, and the future of the randomized controlled clinical trial. Big data is forcing us to think big, senior European regulator Thomas Senderovitz tells the Pink Sheet.
Denmark Leads New EU Task Force Exploring Use Of Big Data In Medicines Assessment
EU drug regulators have created a new task force to establish a roadmap and recommendations on how to use big data in the assessment of medicines.